BNTC Key Statistics, Chart & Performance
The current stock price of BNTC is 12.12 USD. In the past month the price decreased by -0.49%. In the past year, price increased by 15.32%.
BNTC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to BNTC. When comparing the yearly performance of all stocks, BNTC turns out to be only a medium performer in the overall market: it outperformed 53.06% of all stocks.
BNTC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BNTC. BNTC has a great financial health rating, but its profitability evaluates not so good.
BNTC Financial Highlights
Over the last trailing twelve months BNTC reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS increased by 80.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.75% | ||
| ROE | -42.86% | ||
| Debt/Equity | 0 |
BNTC Forecast & Estimates
13 analysts have analysed BNTC and the average price target is 25.7 USD. This implies a price increase of 112.08% is expected in the next year compared to the current price of 12.12.
BNTC Ownership
BNTC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BNTC
Company Profile
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
Company Info
BENITEC BIOPHARMA INC
3940 Trust Way
Hayward CALIFORNIA 94545 US
CEO: Jerel Banks
Employees: 19
Phone: 15107800819
BENITEC BIOPHARMA INC / BNTC FAQ
What does BNTC do?
Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 19 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.
What is the stock price of BENITEC BIOPHARMA INC today?
The current stock price of BNTC is 12.12 USD. The price increased by 4.03% in the last trading session.
Does BENITEC BIOPHARMA INC pay dividends?
BNTC does not pay a dividend.
How is the ChartMill rating for BENITEC BIOPHARMA INC?
BNTC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does BENITEC BIOPHARMA INC have?
BENITEC BIOPHARMA INC (BNTC) currently has 19 employees.
What is BENITEC BIOPHARMA INC worth?
BENITEC BIOPHARMA INC (BNTC) has a market capitalization of 410.38M USD. This makes BNTC a Small Cap stock.